Cosmos Health Inc. (COSM) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Cosmos Health Inc. (COSM) stock forecast summary
Our AI ranks Cosmos Health Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Cosmos Health Inc. is a small-cap company with a market capitalization of $33M. It ranks number 7 by market capitalization among the 7 Wholesale-Drugs, Proprietaries & Druggists' Sundries issuers in our coverage with a current forecast.
For COSM, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 5.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 16.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, COSM included.
Follow COSM freeCOSM price chart and AI forecast
How COSM ranks among 5172 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Cosmos Health Inc. (COSM) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Wholesale-Drugs, Proprietaries & Druggists' Sundries peers listed below that report each metric.
Valuation & Market
| Metric | COSM | Rank |
|---|---|---|
| Market Cap | $33M | 7/7 |
| P/B Ratio | 1.61x | – |
| EPS | $-0.24 | – |
| Book Value/Share | $0.21 | – |
Profitability & Margins
| Metric | COSM | Rank |
|---|---|---|
| ROE | -94.8% | – |
| ROA | -31.9% | 6/7 |
| ROIC | -36.0% | 5/5 |
| Gross Margin | 9.4% | 4/7 |
| Operating Margin | -13.5% | 6/6 |
| Net Margin | -27.6% | 6/7 |
| EBT Margin | -24.0% | 6/7 |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | COSM | Rank |
|---|---|---|
| Current Ratio | 1.05x | 4/6 |
| Quick Ratio | 0.92x | 3/6 |
| D/E Ratio | 1.97x | – |
| Financial Leverage | 2.97x | – |
| Interest Coverage | -6.6x | 6/6 |
| Working Capital | $2M | 3/6 |
Cash Flow
| Metric | COSM | Rank |
|---|---|---|
| Operating Cash Flow | -$6M | 7/7 |
Operational Efficiency
| Metric | COSM | Rank |
|---|---|---|
| Inventory Turnover | 13.8x | 4/6 |
| Days Inventory | 27 days | 3/6 |
| Payables Period | 80 days | 1/5 |
Income Statement
| Metric | COSM | Rank |
|---|---|---|
| Operating Income | -$10M | 5/6 |
| Net Income | -$20M | 6/7 |
| R&D Expense | $160K | – |
| SG&A Expense | $11M | 6/6 |
| Cost of Goods Sold | $62M | 6/7 |
Dividend & Shareholder Information
| Metric | COSM | Rank |
|---|---|---|
| Shares Outstanding | 101M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $37M | 59.7% of assets |
| Cash & Short-term Investments | $2M | 2.9% of assets |
| Accounts Receivable | $19M | 30.7% of assets |
| Inventory | $5M | 7.4% of assets |
| Total Liabilities | $41M | 66.4% of assets |
| Short-term Debt | $21M | 34.4% of assets |
COSM quarterly financials and insider trading
Cosmos Health Inc. (COSM) industry peers
Companies classified under the same SEC industry code as Cosmos Health Inc. (Wholesale-Drugs, Proprietaries & Druggists' Sundries): 7 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up freeWhere COSM sits on the market map
Cosmos Health Inc. (COSM) stock news
Loading...
Cosmos Health Inc. (COSM) stock forecast FAQ
What is the Cosmos Health Inc. (COSM) stock forecast?
Our AI ranks Cosmos Health Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Cosmos Health Inc. stock predictions?
For COSM, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 5.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 16.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Cosmos Health Inc. forecasts updated?
Cosmos Health Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Cosmos Health Inc.'s industry peers?
7 issuers in our coverage, COSM included, share the SEC industry code Wholesale-Drugs, Proprietaries & Druggists' Sundries. The largest are: Mckesson Corp (MCK), Cencora, Inc. (COR), Cardinal Health Inc (CAH), Herbalife Ltd. (HLF), Nu Skin Enterprises, Inc. (NUS), Hwh International Inc. (ESYN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.